It is remarkable that, except for ALT, the panel of biomarkers distinguishing the steatosis and fibrosis groups is completely distinct from the panel distinguishing the non-NAFLD and steatosis groups (Table 3). Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.